Larimar Therapeutics Inc (LRMR)
9.39
-0.30
(-3.10%)
USD |
NASDAQ |
Jun 14, 16:00
9.38
-0.01
(-0.11%)
After-Hours: 20:00
Larimar Therapeutics Cash from Investing (Quarterly): -68.36M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -68.36M |
| December 31, 2023 | -2.629M |
| September 30, 2023 | -46.43M |
| June 30, 2023 | -9.838M |
| March 31, 2023 | 92.25M |
| December 31, 2022 | -52.23M |
| September 30, 2022 | -3.384M |
| June 30, 2022 | -35.34M |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 6.49M |
| September 30, 2021 | -6.791M |
| June 30, 2021 | 19.22M |
| March 31, 2021 | 5.251M |
| December 31, 2020 | -23.54M |
| September 30, 2020 | -0.008M |
| June 30, 2020 | 41.42M |
| March 31, 2020 | -0.778M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-68.36M
Minimum
Mar 2024
92.25M
Maximum
Mar 2023
-4.983M
Average
-2.629M
Median
Dec 2023
Cash from Investing (Quarterly) Benchmarks
| Biogen Inc | -66.00M |
| Eli Lilly and Co | -1.178B |
| PTC Therapeutics Inc | -114.93M |
| Design Therapeutics Inc | 20.62M |
| CEL-SCI Corp | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -10.41M |
| Cash from Financing (Quarterly) | 162.15M |
| Free Cash Flow | -36.32M |
| Free Cash Flow Per Share (Quarterly) | -0.1944 |
| Free Cash Flow Yield | -8.35% |